Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis by Wantong Yao et al.
Yao et al. Molecular Cancer 2014, 13:187
http://www.molecular-cancer.com/content/13/1/187RESEARCH Open AccessProfilin-1 suppresses tumorigenicity in pancreatic
cancer through regulation of the SIRT3-HIF1α axis
Wantong Yao1,2,3†, Shunrong Ji1,2,3†, Yi Qin1,2,3†, Jingxuan Yang4, Jin Xu1,2,3, Bo Zhang1,2,3, Wenyan Xu1,2,3,
Jiang Liu1,2,3, Si Shi1,2,3, Liang Liu1,2,3, Chen Liu1,2,3, Jiang Long1,2,3, Quanxing Ni1,2,3, Min Li1,2,3,4 and Xianjun Yu1,2,3*Abstract
Background: Tumor cells exhibit abnormal actin remodeling profiles, which involve the altered expressions of
several important actin-binding proteins. Profilin1 (Pfn1), originally identified as an actin-associated protein, has been
linked to several human malignancies. Our recent studies suggested that Pfn1 facilitates apoptosis in pancreatic
cancer cells. Here, we investigated the exact role of Profilin1 (Pfn1) in pancreatic adenocarcinoma (PDAC) and the
underlying mechanisms.
Methods: Pfn1 protein expression in PDAC specimens was analyzed by immunohistochemistry using a tissue
microarray (TMA) containing PDAC tumor tissue and corresponding normal tissue samples from 72 patients. The
effect of Pfn1 expression on cancer proliferation was assessed in cells by up- and down-regulation of Pfn1 in vitro
and in vivo. Immunoprecipitation and mass spectrometry were used to identify the Pfn1-associated proteins and
potential pathways.
Results: Pfn1 was downregulated in clinical pancreatic adenocarcinoma specimens compared with the surrounding
benign tissues. Univariate survival analysis of the PDAC cohorts showed that low expression of Pfn1 was
significantly correlated with shortened patient survival (mean 14.2 months versus 20.9 months, P < 0.05). Restoration
of Pfn1 in pancreatic cancer cells with low endogenous Pfn1 expression resulted in a nontumorigenic phenotype,
suggesting that Pfn1 may be a negative regulator of pancreatic cancer progression. Overexpression of Pfn1 in vivo
decreased the tumor volume in orthotopic xenograft nude mice models. Pfn1 upregulated the expression of SIRT3,
leading to HIF1α destabilization. This data revealed that aberrant Pfn1 expression contributes to pancreatic cancer
progression.
Conclusions: Our data suggest that Pfn1 is a tumor suppressor in pancreatic cancer that acts via a novel
mechanism of regulating the SIRT3-HIF1α axis, independently of its cytoskeleton-related activity.
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Pancreatic cancer is a devastating disease, with the high-
est fatality rate among all cancers and a 5-year overall
survival rate of less than 5%. Although some progress
has been made in surgery, chemotherapy and radiother-
apy in recent decades, the incidence of pancreatic cancer
remains equal to its mortality rate. Pancreatic cancer is* Correspondence: yuxianjun@fudan.edu.cn
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unless otherwise stated.characterized by uncontrolled growth and rapid progres-
sion, and is highly resistant to chemoradiotherapy [1,2].
Despite advances in determining the biology of pancreatic
cancer’s development, little is known about its mecha-
nisms of cell proliferation and signal transduction path-
ways. Thus, there is an urgent need to understand more
about the pathogenesis of pancreatic cancer and to
develop new and effective treatments.
The dynamic remodeling of the actin cytoskeleton is
involved in multiple cellular functions, such as motility,
division, and endocytosis [3,4]. Moreover, the dynamic
equilibrium between monomeric and filamentous actin
is altered in neoplastic and/or transformed cells. These. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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many different classes of actin-binding proteins (ABPs)
[5,6]. Profilin1 (Pfn1), an indispensable and ubiquitously
expressed actin-binding protein, has roles in normal cell
motility, proliferation and differentiation [7-11]. Down-
regulation of Pfn1 expression has been implicated in
many types of epithelial-derived tumors, including those
originating in the breast, pancreas, liver and bladder
[12-15]. Most previous studies focused on investigating
Pfn1’s roles and interactions with actin, polyproline
ligands and phosphoinositide [16-18]. In addition, a
tumor-suppressive action of Pfn1 on breast cancer cell
lines was reported, with a novel finding that Pfn1 over-
expression was associated with a dramatic upregulation
of p27 levels [19]. In this study, we validated Pfn1 as a
tumor-suppressor in pancreatic cancer, and identified aFigure 1 Downregulation of Pfn1 in pancreatic cancer correlates with
pairs of pancreatic cancer tissues (T) and their corresponding adjacent non
internal control. (B) Representative micrographs showing low Pfn1 express
Pfn1 in the corresponding adjacent non-cancerous tissues (Magnification, ×
level and cancer-specific survival of pancreatic cancer patients with high (n
normal, well, moderately, and poorly differentiated tumors (Magnification, ×novel mechanism of PFN1 regulation of the SIRT3-
HIF1α axis, independent of its cytoskeleton-related
activity.
Results
Expression of Pfn1 is decreased in pancreatic cancer
tissues
Quantitative real-time PCR was used to analyze Pfn1
expression profiles of 40 paired pancreatic cancer tis-
sues. Pfn1 expression was downregulated in more than
half of the tumors examined (29/40) when compared
with their adjacent non-cancerous tissue (p < 0.001,
Figure 1A). Immunohistochemistry (IHC) and western
blotting were then used to examine the expression of
Pfn1 in pancreatic cancer tissues and corresponding ad-
jacent non-cancerous tissues. Consistent with the resultspoor patient survival. (A) QPCR analysis of Pfn1 expression in 40
-cancerous tissues (ANT). GAPDH mRNA expression was used as an
ion in pancreatic cancer and high levels of cytoplasmic expression of
400). (C) Kaplan-Meier analysis of the correlation between the Pfn1
= 37) and low (n = 35) Pfn1 expression. (D) Representative images of
400).
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lated when compared with the corresponding adjacent
non-cancerous tissues (Figure 1B and Additional file 1:
Figure S1A).
To elucidate the clinical relevance of Pfn1 in pancre-
atic cancer, we analyzed a cohort of 72 pancreatic cancer
specimens using IHC with a Pfn1-specific antibody. Pfn1
is expressed predominantly in the cytoplasm, and two
independent pathologists scored its expression in a semi-
quantitative manner incorporating both staining intensity
and distribution (Additional file 1: Figure S1B). Pfn1
expression levels were strongly associated with cancer-
specific survival. Patients with high Pfn1 expression
had significant better cancer-specific survival than patients
with low Pfn1 expression (Figure 1C). In addition, Pfn1
expression was inversely correlated with tumor differenti-
ation (Figure 1D and Table 1). However, no significant as-
sociation was found between Pfn1 expression and tumor
size, lymph node metastasis or vessel invasion (Table 1,




<60 30 15 (20.8%)
≥60 42 20 (27.8%)
Gender
Female 25 9 (12.5%)
Male 47 26 (36.1%)
Tumor size (cm)
<4.0 47 24 (33.3%)
≥4.0 25 11 (15.3%)
Tumor differentiation
Well 13 3 (4.2%)
Moderate 43 18 (25.0%)
Poor 16 14 (19.4%)
Lymph node status (stage)
Negative (IIA) 44 18 (25.0%)
Positive (IIB) 28 17 (23.6%)
Vessel Infiltration
Negative 56 24 (33.3%)
Positive 16 11 (15.3%)
Nerve Infiltration
Negative 17 9 (12.5%)
Positive 55 26 (36.1%)
Median survival (in months) 14.2
aP values were derived using Pearson chi-square tests.
bP values were derived using a log rank test.
All statistical tests are two sided.
Abbreviations: Pfn1 Profilin-1.Pfn1 in pancreatic cancer may play a role in cell differ-
entiation, proliferation and progression.
Pfn1 attenuates pancreatic cancer cell proliferation
in vitro
Our clinical findings suggested that Pfn1 might play a
role in the tumor differentiation and progression of pan-
creatic cancer. Therefore, we evaluated the function of
Pfn1 in cell proliferation. We selected MIA PaCa-2 cells
with relatively low expression of Pfn1 and SW1990 cells
with high Pfn1 expression compared with that in human
pancreatic ductal epithelium (HPDE) cells (Figure 2A).
Cells with Pfn1 overexpression and downregulation were
established separately using a lentiviral infection system
(Additional file 2: Figure S2A). Cell proliferation assays
revealed that overexpression of Pfn1 significantly at-
tenuated pancreatic cancer cell proliferation (P < 0.05,
Figure 2C). Conversely, downregulation of Pfn1 pro-
moted proliferation (P < 0.05, Figure 2D). To further




























Figure 2 Overexpression of Pfn1 suppresses pancreatic cancer cell proliferation. (A)Western blot analysis of Pfn1 expression in five pancreatic
cancer cells from the ATCC and human pancreatic ductal epithelium (HPDE) cells. α-tubulin was used as a loading control. (B) Pfn1 expression
in BxPC-3/BxPC-3-LN and SW1990/SW1990HM cells. (C-D) Effect of Pfn1 overexpression and downregulation on the proliferation of MIA PaCa-2
and SW1990 cells. (E-F) Effect of Pfn1 overexpression on the proliferation of BxPC-3-LN and SW1990HM cells. (Error bars represent mean ± SD
from three independent experiments. *: p < 0.05)
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and liver metastatic properties, BxPC-3-LN and SW1990-
HM separately. Compared with their parental BxPC-3 and
SW1990 cells, BxPC-3-LN and SW1990-HM expressed
lower levels of Pfn1 (Figure 2B). Furthermore, overex-
pression of Pfn1 also significantly attenuated cell prolif-
eration in these two cell lines (Figure 2E-F; Additional
file 2: Figure S2B).
Pfn1 inhibits pancreatic cancer growth in vivo
We next examined the in vivo effects of Pfn1 expression
on tumor growth. Pancreatic cancer cells were orthotopi-
cally injected into the pancreas of nude mice. At theexperiment endpoint, the control group had tumors with
significantly larger volumes than the Pfn1-overexpressing
group (Figure 3A). This was confirmed by the weights of
dissected tumors (Figure 3B), strongly suggesting a de-
crease in tumor cell growth caused by Pfn1 overexpres-
sion. Conversely, downregulation of Pfn1 in SW1990 cells
promoted tumor growth subcutaneously (Figure 3C-F).
The reversal of the Pfn1 overexpression phenotype by
Pfn1 knockdown (KD) further demonstrated that Pfn1 ex-
erts a growth-suppressive function in human pancreatic
cancer. Accordingly, the level of proliferation related mol-
ecules, such as Ki67, PCNA and c-Myc, decreased after
Pfn1 overexpression (Additional file 2: Figure S2C).
Figure 3 The effect of Pfn1 expression on tumor growth of pancreatic cancer cell xenografts in vivo. (A) Representative micrographs of
MIA PaCa-2-Ctrl (left) & MIA PaCa-2-Pfn1 (right) orthotopically injected nude mice. (B) Each tumor formed by the indicated cells was weighed.
(C-D) Representative micrographs of SW1990-Ctrl & SW1990-shPfn1 subcutaneously injected nude mice. (E) Effect of Pfn1 knockdown (KD) on
pancreatic cancer growth. (F) Each tumor formed by the indicated cells was weighed. Data are presented as mean ± SD from 5 mice in each
group. *: P < 0.05.
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In an effort to further understand the physiological func-
tions of Pfn1, we employed immunoprecipitation followed
by mass spectrometry to identify the binding proteins.
We co-purified a number of proteins that potentially
interacted with Pfn1 (Figure 4A). The protein bands
were retrieved and subjected to mass spectrometry to
identify the candidate proteins. Forty-six proteins were
identified (Additional file 3: Table S1). These proteins
are involved in diverse cellular functions, such as mi-
tochondrial associated physiological processes, tran-
scriptional control of genes, and endocytosis. Further
bioinformatic analysis suggested that Pfn1 might be in-
volved in the process of glycolysis mediated by HIF1α
(Figure 4B).Pfn1 interacts physiologically with SIRT3
According to our previous study, PFN1 enhanced the
apoptosis of pancreatic cancer cells through a mitochon-
drial pathway [20]. Interestingly, 11 mitochondrial pro-
teins were identified by mass spectrometry (Additional
file 3: Table S1). Among them was SIRT3, a sirtuin with
NAD-dependent deacetylase activity, which is a tumor
suppressor that protects against carcinogenesis by main-
taining mitochondrial integrity and efficient oxidative
metabolism [21]. Recently, Finley [22,23] further found
that SIRT3 could mediate metabolic reprogramming in
human breast cancer cells by destabilizing HIF1α. These
observations led us to hypothesize that Pfn1 might, to-
gether with SIRT3, regulate HIF1α activity and inhibit
tumorigenesis.
Figure 4 Identification of Pfn1 interacting protein candidates. (A) Mass spectrometry analysis of Pfn1-associated proteins. (B) Network of the
identified Pfn1 interacting partners based on bioinformatic analysis.
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bility that Pfn1 interacts with SIRT3 in cancer cells.
Using in vitro GST pull-down assays, we observed phys-
ical interactions between Pfn1 and SIRT3 (Figure 5A).
Next, to test the interactions in intact cells, the associa-
tions between Pfn1 and SIRT3 were analyzed in vivo by
coimmunoprecipitation. Pfn1-FLAG and SIRT3-HA fu-
sion constructs were transiently introduced into the
cancer cell line MIA PaCa-2. Immunoprecipitation with
anti-FLAG M2 affinity beads showed that Pfn1 doesFigure 5 Pfn1 interacts with SIRT3 directly. (A) In vitro GST-pull-down a
between Pfn1 and SIRT3. (C) Transfection of exogenous Pfn1 resulted in inassociate with SIRT3 in vivo (Figure 5B). Moreover, we
found that transfection of Pfn1 resulted in an increased
SIRT3 protein level (Figure 5C). These results suggested
that the interaction between Pfn1 and SIRT3 is specific.
Pfn1 negatively regulates HIF1α protein levels via SIRT3
directly
Firstly, we first performed a dual-luciferase assay to deter-
mine whether the HRE promoter activity would change as
a result of increasing Pfn1 expression in HEK-293 T cells.ssay. (B) Co-immunoprecipitation assay to verify in vivo interaction
creased SIRT3 expression.
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structs, pcDNA3-HIF1α, and pcDNA3 as the control.
Relative firefly luciferase activities were presented. We ob-
served that overexpressed Pfn1 in HEK-293 T cells inhib-
ited the activation of HRE promoter activity (Additional
file 4: Figure S3). Furthermore, under hypoxia, endogen-
ous HIF1α protein levels were downregulated in Pfn1-Figure 6 Pfn1 increases HIF1α protein degradation via SIRT3. (A-B) Ef
PaCa-2 cells under hypoxia. (C) Immunohistochemical (IHC) staining for Pfn
Pfn1 and HIF1α in slices of implanted tumors formed by the indicated cells
alone or in combination, on HIF1α levels in HEK-293 T cells under normoxi
in combination, on HIF1α levels in HEK-293 T cells under normoxia or hypo
mean ± SD from three independent experiments. *: p < 0.05overexpressed cells. By contrast, in Pfn1-KD cells, HIF1α
protein levels increased markedly (Figure 6A-B). However,
we did not detect changes in HIF1α mRNA levels in Pfn1
overexpressing MIA PaCa-2 cells, which suggested that
Pfn1 exerted a posttranslational effect on HIF1α levels
(Additional file 5: Figure S4). We also observed a sig-
nificant inverse correlation between Pfn1 and HIF1αfects of Pfn1 overexpression and Pfn1 KD on HIF1α protein level in MIA
1 and HIF1α in serial sections of clinical samples. (D) IHC staining for
(magnification, ×400). (E) Effect of transfected Pfn1 and SIRT3, either
a or hypoxia. (F) Effect of transfected Pfn1 and shSIRT3, either alone or
xia. (G) Schematic of the regulation of HIF1α by Pfn1. Error bars represent
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we examined HIF1α expression in mouse specimens and
found that the proportions and staining signals for HIF1α
were substantially lower than those in control tumors, sug-
gesting that the increased HIF1α expression might result
from Pfn1 downregulation in pancreatic cancer (Figure 6D).
How Pfn1 couples with SIRT3 to regulate HIF1α re-
mains uncertain. To further explore the mechanism,
we transfected Pfn1 and SIRT3, either alone or in com-
bination into HEK-293 T cells. As expected, single
transfection of Pfn1 or SIRT3 resulted in decreased
HIF1α levels. Strikingly, cotransfection of Pfn1 and
SIRT3 had no additive effects, and caused only a modest
decrease in the HIF1α level compared with the single
transfected control (Figure 6E). Thus, we hypothesized
that Pfn1 acts upstream on SIRT3 in the regulation of
HIF1α. To test this hypothesis, we examined the influence
of SIRT3 loss on the regulation of HIF1α. We inhibited
SIRT3 expression using a short hairpin RNA (shRNA) and
revealed that dual transfection with Pfn1 and shSIRT3
could not repress HIF1α compared with single transfec-
tions of the shSIRT3 construct (Figure 6F). Taken to-
gether, these results proved that Pfn1 destabilizes HIF1α
via SIRT3.
Multiple reports have documented that HIF1α plays
an important role in the glycolytic process characterized
by malignant tumors [24-26]. Firstly, the mRNA levels
of HIF1α-targeted lactate dehydrogenase A (LDHA) and
Glut1 [28] were markedly decreased in Pfn1 overexpress-
ing MIA PaCa-2 cells (Additional file 6: Figure S5A). Fur-
thermore, we measured the expression of HIF1α target
genes involved in glycolysis, both in MIA PaCa-2 cells and
orthotopic tumor tissues using western blotting and IHC
analysis, respectively. Glucose transporter Glut1, which
are critical for increased glucose uptake and cell prolif-
eration via aerobic glycolysis in tumorigenesis [27],
were reduced in Pfn1 overexpressing MIA PaCa-2 cells
and in mice tissues relative to their controls (Additional
file 6: Figure S5B-C). Pfn1- overexpressing cells dis-
played decreased glucose uptake and lactate production
(Additional file 6: Figure S5D-E), which are important
physiological downstream effects mediated by HIF1α.
Therefore, the data showed that Pfn1 regulates the
stabilization of HIF1α via SIRT3. Additionally, the in-
hibition of crucial HIF1a downstream target genes,
which coordinate aerobic glucose consumption, may
impair cell proliferation and xenograft growth in pan-
creatic cancer.
Discussion
Downregulation of Pfn1 has been previously reported in
breast, hepatic, pancreatic, and bladder cancer, in which it
contributes to the malignant progression of tumor cells.
When overexpressed, it can suppress the proliferation andmigration ability of cancer cells. However, the underlying
molecular mechanism is not clear. Previous studies of
Pfn1 mainly focused on its role in actin polymerization
during cell proliferation and migration. In this study, tis-
sue microarray analysis demonstrated that Pfn1 was sig-
nificantly downregulated in pancreatic cancer, which was
in consistent with previous observations from a proteomic
study [12]. Furthermore, survival analysis revealed that
downregulation of Pfn1 correlated with shorter survival
times for pancreatic cancer patients. In vitro and in vivo
experiments showed that loss of Pfn1 expression contrib-
uted to cell proliferation and tumor growth. When over-
expressed, it significantly suppressed the proliferation of
cancer cells. However, the mechanisms underlying this
effect of Pfn1 in pancreatic cancer have not yet been de-
lineated. Previously, we showed that up-regulation of
Pfn1 could induce apoptosis of pancreatic cancer cells
through a mitochondrial pathway [20]. A recent study
by our group also demonstrated that overexpression of
Pfn1 in pancreatic cancer cells facilitated apoptosis and
repressed autophagy induced by irradiation [29]. Multiple
studies have demonstrated that mitochondrial metabolism
is essential for cell proliferation and tumorigenesis [30,31].
These results suggest a link between Pfn1 and mitochon-
dria in the tumorigenesis of pancreatic cancer.
To explore the mechanisms underlying the inhibition
of pancreatic cancer cell growth mediated by Pfn1, we
used mass spectrometry to identify the potential Pfn1-
interacting proteins. Eleven mitochondrial proteins
were identified, including SIRT3, IDH1, and GOT2. Sir-
tuins are a conserved family of proteins with NAD-
dependent deacetylase and/or mono-ribosyltransferase
activity, which regulate numerous cellular processes, in-
cluding longevity, and various glucose and lipid metabolic
pathways. Mammals express seven sirtuins (SIRT1–7).
The nuclear sirtuins, SIRT1, SIRT6 and SIRT7, regulate
numerous metabolic pathways through deacetylating
the key transcription factors, cofactors and regulators.
The mitochondrial sirtuins, SIRT3, SIRT4 and SIRT5,
regulate the activity of important mitochondrial en-
zymes to maintain energy homeostasis [32]. Among
them, we selected SIRT3 for further investigation be-
cause it is a mitochondria-localized tumor suppressor
required for the maintenance of mitochondrial integrity
and metabolism [21]. As a major mitochondrial deace-
tylase, SIRT3 also regulates the activity of enzymes that
coordinate global shifts in cellular metabolism. SIRT3
promotes the function of the tricarboxylic acid (TCA)
cycle and the electron transport chain, and reduces oxi-
dative stress. Loss of SIRT3 triggers oxidative damage
and metabolic reprogramming to support proliferation
and tumorigenesis [33]. Finley et al. showed that SIRT3
could mediate metabolic reprogramming in human
breast cancer cells by destabilizing HIF1α [22]. In the
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protein-protein interaction network of Pfn1, suggesting
the existence of a potential cross-talk between Pfn1 and
HIF1α stability. To confirm this, under hypoxia, en-
dogenous HIF1α protein levels were downregulated in
Pfn1-overexpressed MIA PaCa-2 cells. By contrast, in
Pfn1-KD cells, HIF1α protein levels increased markedly.
These results prompted us to suggest that Pfn1 might
couple with SIRT3 to regulate HIF1α activity and inhibit
tumorigenesis in pancreatic cancer.
By GST pull-down and coimmunoprecipitation assays,
we confirmed that Pfn1 interacts specifically with SIRT3.
Overexpression of Pfn1 resulted in increased SIRT3
protein levels. We also showed that loss of SIRT3 de-
creased the ability of Pfn1 to destabilize HIF1α, provid-
ing direct evidence of Pfn1’s coupling with SIRT3
signaling in the regulation of HIF1α. Future experi-
ments will determine which motif Pfn1 might act to
regulate SIRT3 expression.
Pancreatic cancer is characterized by low vascular
density and prominent stroma, which is different to
most other cancers. This specificity severely affects
intratumoral perfusion and causes high levels of hyp-
oxia in pancreatic cancer. In the past decade, it has been
revealed that under hypoxic conditions, cancer cells
switch their glucose metabolism pathway away from the
oxygen-dependent tricarboxylic acid (TCA) cycle to
oxygen-independent glycolysis, which is known as
“Warberg effect” [34,35]. This metabolic shift is driven by
the hypoxia-inducible factor-1 (HIF1) through transcrip-
tional activation of glycolytic genes and inhibition of those
promoting oxidative phosphorylation (OXPHOS) [36].
In our study, one of the most interesting findings was
the changes in HIF1α target genes involved in the process
of glucose metabolism. The expressions of GLUT1 and
LDHA were inhibited remarkably after Pfn1 upregulation,
thereby contributing to glycolytic pathways that are crucial
for pancreatic cancer progression.
These results highlight how differences in protein ex-
pression that leads to distinct outcomes in tumors de-
pend on the expression of collaborating proteins. Thus,
the assessment of certain biomarkers for clinical outcomes
may require analysis of the interacting proteins that to-
gether regulate a biological process. In conclusion, we de-
scribed a novel regulatory mechanism whereby pancreatic
cancer proliferation is inhibited by the interaction of Pfn1
and SIRT3 to destabilize HIF1α, which results in reduced
expression of HIF1α target genes that coordinate aerobic
glucose consumption.
Methods
Cell lines and cell culture
Human pancreatic cancer cell lines MIA PaCa-2, SW1990,
BxPC-3, CFPAC-1, and Capan-1 were purchased fromAmerican Type Culture Collection. BxPC-3-LN cells with
lymph node metastasis properties were established pre-
viously in our institute [37]. SW1990-HM cells with
liver metastasis properties were a gift from Prof. Meng
ZQ [38]. MIA PaCa-2 cells were cultured in Dulbecco's
Modified Eagle's Medium (DMEM) supplemented with
10% FBS and 2.5% Horse Serum. SW1990 cells were
cultured in L-15 medium supplemented with 10% FBS.
BxPC-3 cells were cultured in 1640 medium supple-
mented with 10% FBS. CFPAC-1 cells were cultured in
IMDM medium supplemented with 10% FBS. Capan-1
cells were cultured in IMDM medium supplemented
with 20% FBS. The HPDE cell line was cultured in
complete keratinocyte serum-free medium supplemented
with 50 μg/mL bovine pituitary extract (BPE) and
5 ng/mL epidermal growth factor (EGF) (Gibco/Invi-
trogen, Rockville, MD, USA). Hypoxia mimetic conditions
were chemically generated by treating cells with 200 mM
cobalt chloride (CoCl2, Sigma, St. Louis, MI, USA) for
the indicated times. All cell culture media contained
100 U/mL penicillin and 100 mg/mL streptomycin.Tissue specimens
Clinical tissue samples used in this study were diagnosed
histopathologically and clinically at Fudan University
Shanghai Cancer Center from 2010 to 2012. The histo-
logical characterization and clinicopathological staging
of the samples were determined according to the current
International Union Against Cancer (UICC). For the use
of these clinical materials for research purposes, prior
patients’ consents and approval from the Institutional
Research Ethics Committee were obtained. The samples’
clinical information is presented in Table 1.Lentivirus production and host cell infection
To overexpress Pfn1 in pancreatic cancer cells, a lenti-
virus mediated transfection method was employed. In
brief, DNA encoding FLAG tagged Pfn1 was cloned into
the lentiviral vector pCDH-CMV-MCS-EF1-puro and
pCDH-CMV-MCS-EF1-copGFP (SBI, USA) to generate
the pCDH-Pfn1-puro and pCDH-Pfn1-GFP constructs.
Lentiviral particles were generated by co-transfection of
pCDH-Pfn1 constructs with psPAX2 and pMD2.G into
HEK-293 T cells. Pancreatic cancer cells stably expressing
FLAG tagged Pfn1 were obtained by lentiviral infection
and puromycin screening or flow cytometry sorting.
Cloning vector pLKO.1-TRC (Addgene: 10878) was
used to express shRNAs targeting Pfn1 and SIRT3. In
brief, oligonucleotides containing 21 bp targeting Pfn1
(5′- GCATGGATCTTCGTACCAAGA −3′) and SIRT3
(5′- CCCAACGTCACTCACTACTTT −3′) were ligated
into the pLKO.1-TRC cloning vector to generate the
pLKO.1-shPfn1 and pLKO.1-shSIRT3 constructs. pLKO.1-
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shRNA was used as the control. To produce lentiviral parti-
cles, pLKO.1-shPfn1, pLKO.1-shSIRT3, and pLKO.1-shScr
were transfected into HEK-293 T cells with lentiviral pack-
aging vectors psPAX2 and pMD2.G. Lentiviral particles
were harvested by collecting media from HEK-293 T cells.
Pancreatic cancer cell lines were infected with lentiviral par-
ticles, and stable shRNA-expressing cell lines were obtained
by screening with puromycin.
Cell proliferation assay
The Cell Counting Kit-8 (CCK-8; Dojindo) was used to
measure cell proliferation, as previously described [39,40].
RNA isolation and quantitative real-time PCR
Total RNA was prepared using The TRIzol reagent
(Invitrogen, USA). A Takara PrimeScript RT reagent kit
was used to obtain cDNA by reverse transcription.
Quantitative real-time PCR (qPCR) was used to deter-
mine the expression status of candidate genes and
GAPDH, using an ABI 7900HT Real-Time PCR system
(Applied Biosystems, USA). All reactions were run in
triplicate. The primers sets are listed in Additional file 7:
Table S2.
Western blotting
Total proteins (20 μg) were separated by polyacrylamide
gel electrophoresis (PAGE) and blotted onto polyvinyl-
difluoride membranes (Millipore). After blocking with 5%
nonfat milk in PBST at room temperature for 30 minutes,
membranes were probed with primary antibodies. Anti-
bodies against Pfn1, SIRT3, HIF1α, and Glut1 were all
purchased from Epitomics (USA). FLAG, HA, and α-
tubulin antibodies were purchased from Sigma (USA).
All secondary antibodies were obtained from Jackson
ImmunoResearch (USA). After incubation with primary
antibodies, washing with PBST and incubating with sec-
ondary antibodies, immunoblots were visualized using
the ECL detection kit (Millipore) and a ImageQuant
LAS 4000 mini was used to quantify the immunoreac-
tive protein bands.
Mass spectrometry analysis of Pfn1 associated proteins
Whole cell extracts from HEK-293 T cells transiently ex-
pressing FLAG-Pfn1 were subjected to affinity purification
with anti-FLAG antibody that was immobilized on agarose
beads (Sigma, USA). The purified protein complexes were
resolved on SDS-PAGE silver stained, and the bands
retrieved for subsequent mass spectrometry.
Tumorigenesis study
BALB/c-nu mice (5–6 weeks of age, 18-20 g, Shanghai
SLAC Laboratory Animal Co., Ltd.) were housed in sterile
filter-capped cages. Our Institutional Animal Care andUse Committee approved the animal studies. For intra-
pancreatic injections, mice were anesthetized with
2.5% sodium phenobarbitol (50 mg/kg i.p.) and a 0.5-
to 1-cm incision was made in the left subcostal region.
2 × 106 cells in a volume of 50 μl were injected orthoto-
pically into the body of the pancreas. The peritoneum
and skin were closed with a 4.0 surgical suture. A bio-
luminescent imaging method was used to visualize and
monitor the dynamic growth of orthotopically xeno-
grafted pancreatic cancer cells. For the subcutaneous
(s.c.) tumor model, 5 × 106 cells in 100 μl PBS were
injected s.c. into the right or bilateral flanks. Twenty-
eight days post-implantation, the mice were euthanized
and tumors were surgically dissected. The tumor speci-
mens were weighted and fixed in 4% paraformaldehyde.
Samples were then processed for histopathological
examination.
Statistical analysis
All experiments were carried out at least three times.
Data were expressed as the mean ± SD, and the differences
between any two groups were compared using t-tests.
The chi-square test was used to analyze the relationship
between Pfn1 expression and the clinicopathological
characteristics. The survival curve was plotted using the
Kaplan-Meier method and compared by using the log-
rank test. All statistical analyses were carried out using
the SPSS 19.0 statistical software package. P values < 0.05
were considered statistically significant.
Additional files
Additional file 1: Figure S1. (A) Western blot analysis of Pfn1
expression in eight pairs of pancreatic cancer tissues (T) and their
corresponding adjacent non-cancerous tissues (ANT). α-tubulin was used
as a loading control. (B) Representative micrographs showing negative,
weak, intermediate, and strong positive expressions of Pfn1 in pancreatic
cancer tissues and adjacent non-cancerous tissues (Original magnifica-
tion × 400).
Additional file 2: Figure S2. (A) Construction of MIA PaCa-2
transfectants stably expressing Pfn1 and SW1990 transfectants with
shRNAs against Pfn1 using lentivirus infection. (B) Construction of
BxPC-3-LN and SW1990-HM transfectants stably expressing Pfn1 using
lentivirus infection. (C) IHC staining for proliferation-related proteins
(Ki67, PCNA, c-Myc) in slices of implanted tumors formed by
indicated cells (magnification, ×400).
Additional file 3: Table S1. Pfn1 interacting proteins identified by mass
spectrometry.
Additional file 4: Figure S3. A dual-luciferase assay was carried out to
determine the influence of increased Pfn1 expression on the HRE
promoter in HEK293T cells.
Additional file 5: Figure S4. QPCR analysis of HIF1α expression in
indicated cells.
Additional file 6: Figure S5. Pfn1 downregulates downstream target
genes of HIF1α during glycolysis. (A) QPCR analysis of HIF1α downstream
target genes during glycolysis. (B) Western blot analysis of Glut1
expression in the indicated cells. α-tubulin was used as a loading control.
(C) IHC staining for Glut1 expression in slices of implanted tumors formed
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http://www.molecular-cancer.com/content/13/1/187by the indicated cells (magnification, ×400). (D) Glucose uptake in Pfn1-
WT and -OE MIA PaCa-2 cells. (E) Lactate production in Pfn1-WT and -OE
MIA PaCa-2 cells. Error bars represent mean ± SD from three independent
experiments. *: p < 0.05.
Additional file 7: Table S2. Sequences of qRT-PCR primers.
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